ABCIXIMAB
Abciximab is a chimeric monoclonal antibody fragment that inhibits platelet aggregation by irreversibly binding to the glycoprotein IIb/IIIa receptor on platelets. It is used as an adjunctive antithrombotic therapy during percutaneous coronary interventions to reduce the risk of acute ischemic complications. Benefits include potent antiplatelet effects and reduced procedural thrombosis. Main risks include bleeding, thrombocytopenia, and rare allergic reactions, requiring close monitoring. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Abciximab is a chimeric monoclonal antibody Fab fragment that targets the platelet glycoprotein IIb/IIIa receptor complex. By blocking this integrin, it prevents fibrinogen and von Willebrand factor from binding to activated platelets, thereby inhibiting platelet aggregation and thrombus formation. It also binds to the vitronectin receptor, which may contribute to its antithrombotic profile.
Benefits and advantages
Abciximab has been extensively used as an adjunctive antiplatelet therapy in highrisk percutaneous coronary interventions and acute coronary syndromes. Its rapid onset of action and strong inhibition of platelet function make it a powerful tool in interventional cardiology when used in combination with heparin and aspirin.
Side effects and risks
The principal risks are bleeding complications and thrombocytopenia, which may be profound in some patients. Immunogenic reactions, including hypersensitivity and the development of human antichimeric antibodies, can occur, especially upon reexposure. Because of these risks, use is restricted to specialised settings with close haemodynamic and laboratory monitoring.
Professional use only. This biological API is intended for use by licensed manufacturers and healthcare institutions.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C2101H3229N551O673S15 |
|---|---|
| Molecular Weight | 47615 g/mol |
| CAS Number | 143653-53-6 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Abciximab; ReoPro; c7E3 Fab; Abcixifiban; 143653-53-6 |
| IUPAC/Chemical Name | Abciximab (chimeric monoclonal antibody Fab fragment targeting glycoprotein IIb/IIIa receptor) |
| References |
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
